(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 250.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.93%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Abeona Therapeutics's revenue in 2026 is $5,820,000.On average, 9 Wall Street analysts forecast ABEO's revenue for 2026 to be $3,733,002,820, with the lowest ABEO revenue forecast at $2,366,279,376, and the highest ABEO revenue forecast at $5,922,829,568. On average, 9 Wall Street analysts forecast ABEO's revenue for 2027 to be $9,161,502,604, with the lowest ABEO revenue forecast at $7,675,946,045, and the highest ABEO revenue forecast at $11,264,900,082.
In 2028, ABEO is forecast to generate $14,259,973,789 in revenue, with the lowest revenue forecast at $11,684,780,891 and the highest revenue forecast at $17,131,821,607.